Drug Profile
Opicapone - BIAL
Alternative Names: [14C]-BIA 9-1067; BIA-91067; Ongentys; ONO-2370Latest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator BIAL
- Developer BIAL; Neurocrine Biosciences; Ono Pharmaceutical
- Class Antiparkinsonians; Nitrobenzenes; Oxadiazoles; Oxides; Pyridines
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 07 Dec 2023 Amneal Pharmaceuticals and BIAL eneters into a licensing agreement to market and distribute opicapone
- 03 May 2023 Neurocrine Biosciences provides BIAL with written notice of termination of the license agreement to commercialize and market Opicapone in USA and Canada
- 12 May 2021 BIAL initiates enrolment in a phase III EPSILON trial for Parkinson's disease (Adjunctive treatment) in Czech Republic and Bulgaria (EudraCT2020-005011-52)